FluoroPharma Medical, Inc. (FPMI)
FluoroPharma Medical Company Description
FluoroPharma Medical, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of molecular imaging pharmaceuticals with initial applications in the area of cardiology in the United States.
Its product candidates include BFPET, an imaging agent that has completed a Phase I clinical trial in stress-testing for patients with presumptive or proven coronary artery disease (CAD); and CardioPET, a molecular imaging agent, which is in Phase IIa clinical trial to assess myocardial blood flow and metabolism in patients with CAD.
The company has license agreements with Massachusetts General Hospital and Sinotau USA; and clinical research agreements with Pharmaceutical Product Development, LLC, as well as Cardiovascular Imaging Technologies.
FluoroPharma Medical, Inc. was founded in 2003 and is headquartered in Montclair, New Jersey.
| Country | United States |
| Founded | 2003 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 4 |
Contact Details
Address: 8 Hillside Avenue Montclair, Nevada 07042 United States | |
| Phone | 973-744-1565 |
| Website | fluoropharma.com |
Stock Details
| Ticker Symbol | FPMI |
| Exchange | OTCMKTS |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US3438701019 |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| Edward L. Lyons Jr. | Vice President of Development |